



Guideline for fees payable to the Medicines Authority in relation to medicinal products in accordance with Legal Notice 315 of 2006 (Subsidiary Legislation S.L.458.46) – Medicines Authority Fees

Ref No: GL-LI06.05

November 2018

Abbreviations:

AA – Authorisation in accordance with article 126(a)

DCP – Decentralised Procedure

CMS – Concerned Member State

RMS – Reference Member State

MA – Marketing Authorisation

MRP- Mutual Recognition Procedure

PI – Parallel import

PAES – Post Authorisation Efficacy Studies

PASS – Post-Authorisation Safety Studies

PSUR – Periodic Safety Update Report

THMP – Traditional Herbal Medicinal Products

Contents

1. Introduction.....	4
2. Registration of medicinal products to be placed on the market in Malta	4
2.1 European procedure applications for a marketing authorisation where Malta is Reference Member State (RMS) and national procedures	4
2.2 European procedure applications for a marketing authorisation where Malta is a Concerned Member State (CMS).....	6
2.3 Registration of medicinal products to be placed on the market in Malta – other types of applications	6
2.3.1 Application for a new authorisation in accordance with article 126(a) of Directive 2001/83/EC (regulation 4(2) of the Medicines (Marketing Authorisation) Regulations) and renewals	6
2.3.2 Parallel import applications with reference products with a national marketing authorisation (granted through the national, MRP or DCP) and renewals ...	7
2.3.3 Line extensions of products authorised in the transitional period.....	7
The fees for line extensions of national products authorised during the transitional period are €250 per product. Fees for line extensions of purely nationally authorised products incur fees as per table 1.....	7
2.3.4 Traditional Herbal Medicinal Products (THMP) (Chapter 2a of Directive 2001/83/EC).....	7
2.3.5 Homeopathic product registrations (Chapter 2 of Directive 2001/83/EC)	7
3. Post-authorisation Procedures.....	8
3.1 Variations	8
3.1.1 Fees for variations for purely national products (those products not authorised through the transitional arrangements and their line extensions)	8
3.1.2 Variations for procedures where Malta is CMS.....	10
3.1.3 Batch specific variations (for products authorised nationally or via DCP/MRP).....	10
3.1.4 Notifications for variations to products authorised in accordance with article 126(a)/ Variations for Parallel Imported products	10
3.2 Annual maintenance fees and renewal fees.....	10
3.2.1 Malta Reference Member State.....	10
3.2.2 Malta Concerned Member State and national products authorised during the transition period and their line extensions:	11
3.2.3 Annual maintenance fees for other types of registrations – marketing authorisations granted in the transitional period and their line extensions, authorisations in accordance with article 126a and parallel import licences.....	11
3.3 Transfer applications for marketing authorisations.....	11
3.4 Withdrawal applications.....	11
4. Clinical Trial applications.....	12
5. Assessment of PSURs, PAES and PASS.....	12
6. Direct Healthcare Professional Communications	12
7. Reduced fees for alternative products in view of Brexit	12

1. Introduction

This guideline is intended to assist applicants and marketing authorisation holders in identifying the correct fees to be paid for applications for registration of medicinal products for human use, post-authorisation procedures and other medicinal product related fees. A proof of payment is to be submitted with all applications sent to the Licensing Directorate. All fees in the guideline are applicable from 1 January 2015.

2. Registration of medicinal products to be placed on the market in Malta

2.1 European procedure applications for a marketing authorisation where Malta is Reference Member State (RMS) and national procedures

Fees for new applications through the decentralised (DCP) and mutual recognition procedures (MRP) where Malta is Reference Member State (RMS) and for national procedure are included in the table below:

Type of Application	€
Article 8.3 of Directive 2001/83/EC: New active substance*	140,000
Article 8.3 of Directive 2001/83/EC: Known active substance*	125,000
Article 10 (a) of Directive 2001/83/EC (Bibliographic/well established use) application)*	26,000
Article 10 (b) of Directive 2001/83/EC (Fixed combination)*	26,000
Article 10(1) of Directive 2001/83/EC (Generic application)*	23,000
Article 10(3) of Directive 2001/83/EC (Hybrid application)*	23,000
Article 10(c) of Directive 2001/83/EC (Informed consent application)*	17,000
Article 10(4) of Directive 2001/83/EC (Similar biological medicinal product)*	40,000
Article 10(5) of Directive 2001/83/EC (Additional indication)*	26,000
Additional strength (applied for at the same time)	2,000
Additional pharmaceutical form (applied for at the same time)	2,000
Line extension applied for after grant of Marketing Authorisation*	10,000
Parallel application (applied for at the same time)*	10,000
MRP/Repeat use MRP*	10,000
Application withdrawn during validation	Refund of 90% of fees paid

Duplicate application (applied for at the same time as the initial lead procedure)/National Duplicate*	10,000
Change from Malta Concerned Member State to Reference Member State	4,000

Table 1

The fees depend on the legal basis of the application as per the above table.

The fee for additional strengths and forms applied for at the same time (irrespective of the legal basis of the application) is €2,000.

Example: For an application for one pharmaceutical form in two strengths with legal basis article 10(1) of Directive 2001/83/EC the fee to be paid is:

	€
For first product – 25mg tablets	23,000
For the additional strength – 50mg tablets	2,000
For the additional form – oral solution 25mg/5ml)	<u>2,000</u>
Total fees	<u>27,000</u>

A parallel application applied for at the same time incurs a fee of €10,000 with an additional €2,000 for each additional form and strength.

A duplicate application applied for after the start of the first procedure incurs a fee of €23,000 with an additional €2,000 for each additional form and strength.

Applicable discounts:

If the same applicant submits 3 new lead applications nationally or through the decentralised procedure within a 12 month period (dates of submission should be within 12 months from the submission of the first application), a 30% discount is given on submission of the third lead application. These discounts only apply for applications submitted through the national and Mutual Recognition Procedure and Decentralised with Malta as RMS.

Discount for Micro Enterprises

A 30% discount applies for applicants falling under the definition of a micro enterprise given in [Commission Recommendation 2003/361/EC](#) of May 2003 for new applications. This discount is applicable for companies submitting applications through the MRP and DCP with Malta as Reference Member State only marked by * in the above table.

GL-LI06.05

To be able to avail of the discount applicable to micro-enterprises, applicants must provide documentation confirming that the company falls within the definition of a microenterprise, that is, that the company employs fewer than 10 employees and that your annual turnover and/or balance sheet total does not exceed €2 million (Commission Recommendation 2003/361/EC of 6 May 2003). A copy of the audited financial statements for the previous financial year or a letter from the auditors confirming the above would suffice.

The discounts above cannot be availed of at the same time.

A refund of 90% of the fees paid under section 2.1 is given for applications that are withdrawn by the applicant during the validation period or are invalid.

However, no refund will be made by the Medicines Authority if the application proceeds after the validation period and is withdrawn by the applicant any time between Day 0 and the end of the procedure or the procedure has a negative outcome.

2.2 European procedure applications for a marketing authorisation where Malta is a Concerned Member State (CMS)

The fee for each product included in the same procedure is €250 (per form or strength included in the procedure). This fee also applies for line extensions and Day 0 administrative procedures.

2.3 Registration of medicinal products to be placed on the market in Malta – other types of applications

2.3.1 Application for a new authorisation in accordance with article 126(a) of Directive 2001/83/EC (regulation 4(2) of the Medicines (Marketing Authorisation) Regulations) and renewals

	€
New application/renewal	450
Fast track application for authorisation (10 working days)*	1,000

Table 2

The fee for a new registration and for the 5-yearly renewal is €450 per product and per source country.

GL-LI06.05

The possibility of a fast-track application has been introduced for authorisations in accordance with article 126(a). The authorisation will be issued within 10 working days of submission of payment and a valid application form (i.e. the timeline excludes the validation period in which the applicant must submit the correct information/application).

If this option is chosen, please mark the tick-box on the first page of the application when filling in the form. Please note that this option is for products considered critical.

2.3.2 Parallel import applications with reference products with a national marketing authorisation (granted through the national, MRP or DCP) and renewals

	€
New parallel import licence application/renewal	450

Table 3

The fee for a new registration and for the 5-yearly renewal is €450 per product and per source country.

2.3.3 Line extensions of products authorised in the transitional period

The fees for line extensions of national products authorised during the transitional period are €250 per product. Fees for line extensions of purely nationally authorised products incur fees as per table 1.

2.3.4 Traditional Herbal Medicinal Products (THMP) (Chapter 2a of Directive 2001/83/EC)

	€
National simplified registration (Traditional Herbal Medicinal Product Regulations)	582.34
Administrative variations	34.95
Technical variations	69.88

Table 4

2.3.5 Homeopathic product registrations (Chapter 2 of Directive 2001/83/EC)

	€
New product (single stock)	232.94
New product (2 or more stocks)	465.87
Administrative variations	34.94
Technical variations	69.88

Table 5

3. Post-authorisation Procedures

3.1 Variations

3.1.1 Fees for variations for purely national products (those products not authorised through the transitional arrangements and their line extensions)

Type I	€
Type IA	115
Type IB	350
Type II	
Type II Simple	800
Type II Complex	4,000

Table 6

Products authorised through the transitional arrangements and their line extensions may be exempted the fees due if the submission is:

- Accompanied by an approval letter from another EU National Competent Authority (in English and covering the scope of the variation applied for)
- A variation resulting from paediatric worksharing (Article 45/46 of the [Paediatric Regulation](#))
- A variation resulting from a referral on the basis of an article 30 or article 31 of [Directive 2001/83/EC](#)
- A variation following a PSUR worksharing procedure
- A Variation resulting from a referral on the basis of article 107(i) of Directive 2001/83/EC
- A variation concerning a CEP update

If the variation is the result of any of the above, please indicate this clearly in the cover letter.

All variations where Malta is acting as RMS include a fee, as per the table above. The footnotes exempting fees do not apply for RMS variations. The above exemptions are not applicable for procedures where Malta is the RMS.

The definition of complex variations is given in detail in the Fees [Legal Notice](#).

Grouping of variations:

Article 7(2)(a) of the Variations Regulation sets out the possibility for a MAH to group several Type IA/IAIN variations under a single notification to the same relevant authority, or to group them with other types of variations.

GL-LI06.05

Several Type IA and/or IAIN affecting several medicinal products from the same MAH provided that those variations are the same for all medicinal products and are submitted to the same relevant authority.

Type IA/IAIN can also be grouped with other variations (e.g. Type IB, Type II, Extension, as listed in Annex III of Commission Regulation 1234/2008. Groupings not included in the aforesaid Annex should be discussed and agreed with the Agency prior to submission. • Such grouped submissions will follow the review procedure of the highest variation in the group. Only one application needs to be submitted for a grouped variation and the cover letter should indicate that the application is for a grouped variation, as this will have an impact on the fees due. No grouping is necessary for products falling under the same global marketing authorisation undergoing an identical variation. In this case the fee for the single variation applies.

Variations can be grouped in line with the respective [legislation](#) and [grouping guidelines](#).

Examples for Grouped (G) variations:

1. Grouping of different variations for a number of products

For grouped variations, a fee applies for each variation included in the group. However, no fee will apply for the additional products applied for at the same time which are the subject of the same variation.

Example 1

2 x Type IA and 1 x Type IB for 3 strengths

2 x Type IA (€115 + € 115) + € 350 (IB)

For variations including more than one procedure number in the group, a fee applies for only the first strength of every procedure.

2. Grouping of products undergoing the same variation

Example 2

Type IB variation for 3 products

1 type IB variation € 350

Example 3

MT/H/xxxx/IA/__/G (Grouped variation number)

2 variations - Type IA

(Involving procedures MT/H/0001/01-03/DC, MT/H/0002/01-03/DC and MT/H/0003/01-03/DC)

2 x Type IA (€115 + € 115) x 3 procedures

Example 3

Grouping of the same variation for a number of products is also possible. In this case the fee to be paid is the fee for the single variation.

1 type IA variation (identical variation) for 20 products – the fee to be paid is Euros 115.

1 type IB variation (identical variation) for 5 products – the fee to be paid is Euros 350.

3.1.2 Variations for procedures where Malta is CMS

Variations of all types where Malta is CMS do not incur any fee.

3.1.3 Batch specific variations (for products authorised nationally or via DCP/MRP)

Batch specific variations incur the fees for national variations. If the variation does not fall within the categories of the Commission Guideline on the categorisation of variations, the fee for a type IA variation applies.

3.1.4 Notifications for variations to products authorised in accordance with article 126(a)/ Variations for Parallel Imported products

The above notifications do not incur any fee.

3.2 Annual maintenance fees and renewal fees

3.2.1 Malta Reference Member State

Fees for renewals and annual fees for products authorised nationally (excludes the products that were part of the transitional list and their line extensions), and for products authorised with Malta as Reference Member State:

Annual maintenance fees for each product: €800

Renewal for each product (one time renewal, except in cases where the Medicines Authority decides that additional renewals are required), for each product: €1,000

3.2.2 Malta Concerned Member State and national products authorised during the transition period and their line extensions:

The renewal fee for each product is €450.

For injectable medicinal products, where more than one MA number is given to a number of presentations (vial sizes), a single fee of €450 will apply and will cover all presentations.

	€
Annual maintenance fee	275

Table 7

3.2.3 Annual maintenance fees for other types of registrations – marketing authorisations granted in the transitional period and their line extensions, authorisations in accordance with article 126a and parallel import licences

	€
Annual maintenance fee	275

Table 8

3.3 *Transfer applications for marketing authorisations*

A change in legal entity of the holder of a marketing authorisation incurs a fee of €150 irrespective of route of registration. This application applies for products authorised through the transitional arrangements and their line extensions, CMS and RMS.

A variation notification form should be filled in for products authorised in accordance with article 126(a) of Directive 2001/83/EC. For more information please refer to the [relevant section](#) on the website.

3.4 *Withdrawal applications*

Withdrawal applications following the granting of a marketing authorisation do not incur any fees.

4. Clinical Trial applications

	€
Phase 1,2 or 3 patient trial with a known product	1,500
Phase 1,2 or 3 patient trial with a new product	2,000
Phase 4 patient trial	1,500
Amendment/s	150

Table 9

Fees for academic research without support from industry benefit from a fee exemption of 70% of full fee. Decisions on discounts are at the discretion of the Medicines Authority.

5. Assessment of PSURs, PAES and PASS

Other post-authorisation activities (Malta rapporteur/Reference Member State)	€
Assessment of PSURs	2,300
Assessment of Post Authorisation Safety Studies (PASS)	800 (400)
Assessment of Post Authorisation Efficacy Studies (PAES)	800 (400)

Table 10

Fees in brackets are for applications for academic research without financial support from the pharmaceutical industry. Decision will be at the discretion of the Licensing Authority.

The above fees are not applicable if the procedures are also levied a fee at the EMA.

6. Direct Healthcare Professional Communications

A fee of €2,300 is applicable for the Medicines Authority to distribute DHPC communications. This fee covers all products (and companies) which are the subject of the communication.

7. Reduced fees for alternative products in view of Brexit

To encourage companies having products registered in accordance with article 126(a) or through parallel import licences to find alternative sources in view of the fact that the United Kingdom becomes a third country on 30 March 2019, the Medicines Authority is reducing fees for registration of alternative products sourced from a country within the EU.

1. The product is equivalent (falls under the same Global Marketing Authorisation and is of the same strength and pharmaceutical form) to the one currently authorised sourced from the UK – fee per product **€100**
2. The product is a different product (having same active substance, pharmaceutical form and strength but different brand/MAH i.e. different dossier, different product information) to the one in the UK currently authorised – fee per product **€250**

These fees will apply until 28 February 2019.

To encourage companies to switch RMSship from the United Kingdom to Malta where Malta is Concerned Member State, switching/splitting fees for procedures currently with UK as RMS will be waived until 28 February 2019.